DUSP22

Across TCGA pan-cancer cohorts, DUSP22 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DUSP22 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DUSP22 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DUSP22 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, LUAD, and GBM are the cancer types where DUSP22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.837	0.582	<.001	43	view →
LUAD	OS	Median	II,III,IV	0.795	1.000	.005	35	view →
GBM	DFS	Median	All	0.326	0.197	.014	8	view →
CCRCC	OS	Quartile	All	1.000	0.795	.024	7	view →
LSCC	OS	Median	All	0.938	0.824	.035	3	view →
UCEC	OS	Median	All	0.961	0.861	.032	2	view →
PDAC	OS	Tertile	All	0.755	0.881	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DUSP22–HNSC (OS)

Open the HNSC breakdown →